The ANTICOV clinical trial aimed to identify treatments that could be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalizations that could overwhelm fragile and already overburdened health systems in low-resource settings.
The trial was launched in September 2020 in 13 countries by the ANTICOV consortium. The consortium included 27 prominent global research and development organizations, coordinated by the Drugs for Neglected Diseases initiative (DNDi).
One of the largest multi-country trials focusing exclusively on mild and moderate cases of COVID-19, ANTICOV helped address the relative neglect of clinical research during the COVID-19 pandemic in Africa, Asia, and Latin America. ANTICOV employed an innovative ‘adaptive platform’ trial design which allowed the consortium to add or remove treatments as evidence emerged.
